RecruitingNot ApplicableNCT06329050
The Effects of Losartan on Attention Control: An Eye-tracking Study
Sponsor
University of Electronic Science and Technology of China
Enrollment
80 participants
Start Date
Mar 5, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The main aim of the present study is to investigate the effects of orally administered Losartan on bottom-up and top-down attentional control to socio-emotional stimuli by combining a validated saccade/antisaccade eye-tracking paradigm with a randomized between-subject placebo-controlled pharmacological trial design.
Eligibility
Min Age: 18 YearsMax Age: 40 Years
Inclusion Criteria2
- Healthy subjects who volunteer to participate and are able to fully understand and agree with this study by written informed consent.
- Normal or corrected-normal version
Exclusion Criteria12
- History of neuropsychiatric diseases.
- History of cardiac disease, including arrhythmias, aortic stenosis, or congestive heart failure; history of syncope or unexplained loss of consciousness.
- History of hepatic diseases, including cholestasis, biliary obstructive disease, or severe liver dysfunction.
- History of renal diseases, including renal stones or renal failure.
- History of hyponatremia(Serum sodium <135mmol/L) or hyperkalemia (Serum potassium>5.5mmol/L); history of diabetes mellitus or diabetes insipidus
- Known hypersensitivity or allergic reaction to any medication or hormone; strong allergic reaction to food.
- Infections such as COVID-19 or influenza, or unexplained fever.
- Subjects with hypertension (BP ≥130/80mmHg) or hypotension (BP ≤ 90/60mmHg).
- History of alcohol or drug abuse; smoker (≥ 10 cigarettes or ≥ 3 cigars or ≥ 3 pipes/day); smoker using e-cigarettes.
- Blood donation (≤ 1 month prior to administration).
- Take oral contraceptives or receive hormonal medications in the three months prior to the experiment.
- Pregnant or breastfeeding.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGLosartan
Administration of Losartan tablets(50 mg)
DRUGPlacebo
Administration of Placebo tablets
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06329050
Related Trials
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
NCT071696301 location
BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies
NCT07160244158 locations
Predicting Future Errors During Skill Performance
NCT067072071 location
Study of New Magnetic Resonance Imaging Methods of the Brain
NCT000045771 location
A Study of [14C]-LY4064809 in Healthy Participants
NCT075195251 location